FINWIRES · TerminalLIVE
FINWIRES

$BSX

65 stories mentioning BSXUpdated 9h ago

Every FINWIRES story that references BSX, newest first.

Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Wednesday afternoon with the NYSE Healthcare Index gaining 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, BioNTech's (BNTX) cancer-drug pipeline is showing stronger early results and is approaching several important clinical milestones, improving confidence in the company's long-term outlook, UBS Securities said. BioNTech shares rose 1.4%.Corcept Therapeutics (CORT) shares jumped 9.7% after the company said it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome.Boston Scientific (BSX) shares slumped 12% after CEO Mike Mahoney said this year has been "a bit more of a challenge" than anticipated.Guardant Health (GH) shares gained 5.6% after the company said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.

$BNTX$BSX$CORT$GH
Wire

Nephron Research Cuts Boston Scientific Price Target to $75 From $85

Boston Scientific (BSX) has an average rating of buy and mean price target of $83.63, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $50.37, Change: $-7.27, Percent Change: -12.62%

$BSX
Wire

Baird Lowers Boston Scientific Price Target to $70 From $75

Boston Scientific (BSX) has an average rating of buy and mean price target of $83.63, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $50.35, Change: $-7.29, Percent Change: -12.65%

$BSX
Wire

Top Midday Decliners

Zscaler (ZS) shares plunged 31% intraday after the company issued a fiscal Q4 revenue outlook that missed analysts' expectations late on Tuesday.The stock remains in the penalty box until further evidence of traction emerges in the security operations business, new sales leader roles are filled, and the operating structure improves, Morgan Stanley said in a research report.Shares sank 31% following a surge in intraday trading volume to over 23.9 million from a daily average of about 3.05 million.Verra Mobility (VRRM) cut its 2026 outlook following car rental firm Avis Budget's (CAR) decision to terminate a contract with the company, effective September.Shares slumped 71% as intraday trading volume advanced to more than 56.7 million from a daily average of about 1.7 million.Boston Scientific's (BSX) Chief Executive Mike Mahoney said at an industry conference that this year has been "a bit more of a challenge" than anticipated.Stifel cut its price target to $75 from $85 while keeping its buy rating. Goldman Sachs also cut its price target to $81 from $84.Shares dropped 13%, with intraday trading volume at over 34.1 million versus a daily average of about 16.5 million.Price: $126.73, Change: $-57.88, Percent Change: -31.35%

$BSX$VRRM$ZS
Sectors

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index up 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.2%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, Corcept Therapeutics (CORT) shares jumped past 6% after the firm said Wednesday it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome, also known as hypercortisolism.Boston Scientific (BSX) shares slumped 12% after Chief Executive Mike Mahoney said this year has been "a bit more of a challenge" than anticipated.Guardant Health (GH) shares gained 5.8% after the firm said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.

$BSX$CORT$GH
Asia Markets

US Equity Indexes Trade Mixed Amid Sharp Sell-Off in Crude Oil

US equity indexes traded mixed but were off session lows amid a sharp decline in crude oil prices and a retreat in government bond yields.The Dow Jones Industrial Average rose 0.4% to 50,675.1 after midday on Wednesday. The Nasdaq Composite declined 0.2% to 26,596.5, and the S&P 500 was down 0.1% at 7,509.9. Both the Nasdaq and the S&P 500 traded lower earlier in the session.Energy and financials led the decliners intraday, while consumer discretionary and consumer staples topped the gainers. Technology recovered partially from intraday declines.The memorandum of understanding being negotiated between Tehran and Washington will call for US forces to withdraw from Iran's vicinity and lift the blockade of Iranian ports in return for reopening the Strait of Hormuz to pre-war levels, CNN reported, citing Iranian state television. The US denied claims that maritime traffic through the Strait of Hormuz could return to normal within a month of the Iran deal, Bloomberg reported.During an ongoing Cabinet meeting on Wednesday, President Donald Trump said he won't be rushed into a deal, warning that Iran's efforts to outlast him won't work because he doesn't "care about the midterms," CNN reported.West Texas Intermediate crude oil futures dropped 4.3% to $89.85, and Brent crude futures slumped 4.1% to $95.54.Most US Treasury yields fell, with the 10-year down 1.6 basis points to 4.47% and the two-year lower by 2.1 basis points to 4.03%.In economic news, Redbook US same-store sales jumped 9% from a year earlier in the week ended May 23 after an 8.1% gain in the prior week. "Demand for a wide variety of summer, home and garden, and seasonal apparel products was the main focus for most consumers," Redbook said.The Dallas Federal Reserve's monthly general business services index improved to minus 7.7 in May from minus 9.9 in April, versus the minus 6.0 anticipated.The Richmond Fed's monthly manufacturing index rose to 13 in May from 3 in April, more than the 4 estimate in a Bloomberg-compiled survey.In company news, Boston Scientific (BSX) shares sank 12%, the worst performer on the S&P 500, after Chief Executive Mike Mahoney said at an industry conference that this year has been "a bit more of a challenge" than anticipated. Stifel adjusted its price target on Boston Scientific shares to $75 from $85 while maintaining its buy rating, a move mirrored by Goldman Sachs.Zscaler (ZS) stock plunged 31%, the steepest decline in the Nasdaq, after the company issued a fiscal Q4 revenue outlook that missed analysts' expectations. Zscaler stock remains in the penalty box until further evidence of traction emerges in the security operations business, new sales leader roles are filled, and the operating structure improves, Morgan Stanley said in a research report.In precious metals, gold futures dropped 1.4% to $4,440.1, while silver futures dropped 2.3% to $74.82.

Dow JonesNasdaq CompositeS&P 500$BSX$ZS
Wire

Top Midday Stories: White House Refutes Iran Report of Interim Peace Deal; Zscaler Shares Plunge After Fiscal Q4 Revenue Guidance Misses Estimates

The Dow Jones Industrial Average was up, while the S&P 500 and Nasdaq Composite were about flat in late-morning trading Wednesday after Iranian state media reported that an unofficial draft of a US-Iran interim peace deal says that maritime traffic through the Strait of Hormuz would return to normal within a month of the agreement being finalized. Later, the White House said the report of an interim peace deal was a "complete fabrication" and "not true."In company news, Zscaler (ZS) reported fiscal Q3 adjusted earnings late Tuesday of $1.08 per diluted share, up from $0.84 a year earlier and above the FactSet consensus analyst estimate of $1.01. Fiscal Q3 revenue was $850.5 million, up from $678 million a year ago and above the FactSet consensus of $835.6 million. For fiscal Q4, the company said it expects adjusted EPS of $1.08 to $1.09, above the FactSet consensus of $1.03. Fiscal Q4 revenue is expected to be between $875 million and $878 million, below the FactSet consensus of $878.6 million. For full-year 2026, the company said it expects adjusted EPS of $4.10 to $4.11, up from its previous guidance of $3.99 to $4.02 and above the FactSet consensus of $4.01. Full-year revenue is expected to be between $3.329 billion and $3.332 billion, above its previous guidance of $3.31 billion to $3.32 billion and above the FactSet consensus of $3.32 billion. Zscaler shares were down 31.6% around midday.Boston Scientific (BSX) Chief Executive Mike Mahoney mentioned possible short-term challenges facing the company during a presentation Wednesday at an industry conference. Mahoney said Boston Scientific is "not going to likely grow faster than our peer group in the short term, but as that Denali platform gets launched in our emblem with [subcutaneous implantable cardioverter defibrillator] leadless pacemaker, that will help our growth in our [cardiac rhythm management] business," according to the report. Boston Scientific shares were down 9.8%.PDD Holdings (PDD) reported Q1 non-GAAP earnings Wednesday of 9.51 Chinese renminbi ($1.38) per diluted American depositary share, down from 11.41 renminbi a year earlier and below the FactSet consensus of 16.56 renminbi. First-quarter revenue was 106.23 billion renminbi, up from 95.67 billion renminbi a year ago but below the FactSet consensus of 109.82 billion renminbi. PDD shares were down 11.0%.JPMorgan Chase (JPM) CEO Jamie Dimon said Wednesday at a conference that "there might be in the next couple of years a chance to put $10 billion or $20 billion to work buying" another company, according to a transcript. JPMorgan shares were down 3.0%.Dycom Industries (DY) reported fiscal Q1 adjusted net income Wednesday of $4.42 per diluted share, up from $2.39 a year earlier and above the FactSet consensus of $2.72. Fiscal Q1 contact revenue was $1.96 billion, up from $1.26 billion a year ago and above the FactSet consensus of $1.67 billion. For fiscal 2027, the company said it expects revenue of $7.38 billion to $7.65 billion, up from its previous guidance of $6.85 billion to $7.15 billion and above the FactSet consensus of $7.07 billion. Dycom shares were up 28.1%.Price: $126.28, Change: $-58.33, Percent Change: -31.60%

$BSX$DY$JPM$PDD$ZS
Wire

Boston Scientific Shares Fall as CEO Flags Short-Term Challenges

Boston Scientific (BSX) shares fell 9% in Wednesday trading after Chief Executive Mike Mahoney said this year has been "a bit more of a challenge" than anticipated.Mahoney said at an industry conference Wednesday that the company is "not going to likely grow faster than our peer group in the short term, but as that Denali platform gets launched in our emblem with [subcutaneous implantable cardioverter defibrillator] leadless pacemaker, that will help our growth in our [cardiac rhythm management] business," according to a FactSet transcript.Price: $52.44, Change: $-5.20, Percent Change: -9.02%

$BSX
Wire

Stifel Adjusts Price Target on Boston Scientific to $75 From $85, Maintains Buy Rating

Boston Scientific (BSX) has an average rating of buy and mean price target of $83.63, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $51.58, Change: $-6.06, Percent Change: -10.51%

$BSX
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding about 1.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In sector news, Boston Scientific (BSX) shares gained 1.9% after the company said Tuesday a trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the company said. Its shares rose 3%.UroGen Pharma's (URGN) investor event reinforced the commercial thesis for Zusduri in low-grade intermediate-risk non-muscle invasive bladder cancer, with a physician panel suggesting that peers may face tough competition unless they can offer overwhelmingly better efficacy, Oppenheimer said in a note. UroGen shares were down 0.8%.MetaVia (MTVA) shares surged 64% Tuesday, a day after the company said three late-breaking abstracts highlighting its cardiometabolic assets were accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions.

$BSX$MTVA$TLSA$URGN
Sectors

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) gaining 1.2%.The iShares Biotechnology ETF (IBB) increased 0.5%.In sector news, Nourish, a nutrition counseling startup focused on supporting patients using GLP-1 weight-loss drugs, raised $100 million in a Series C funding round led by Menlo Ventures, the company said Tuesday. The round included participation from Thrive Capital, Index Ventures, JPMorgan Chase's (JPM) growth equity arm, Maverick Ventures, Y Combinator and others, the company said.In corporate news, Boston Scientific (BSX) shares gained 1.4% after the company said Tuesday that a trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.Relay Therapeutics (RLAY) shares climbed 5.2% after it said early phase 2 data showed its experimental drug zovegalisib reduced lesion volume in patients with rare vascular anomalies linked to PIK3CA mutations.Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the company said. Its shares rose 3.7%.MetaVia (MTVA) shares were up 58% in Tuesday trading, a day after the company said three late-breaking abstracts highlighting its cardiometabolic assets were accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions.

$BSX$MTVA$RLAY$TLSA
Sectors

Sector Update: Healthcare

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding 1.1%.The iShares Biotechnology ETF (IBB) increased 0.6%.In corporate news, Boston Scientific (BSX) shares gained nearly 1% after it said Tuesday that a trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.

$BSX
Wire

Leerink Partners Adjusts Boston Scientific PT to $87 From $86, Maintains Outperform Rating

Boston Scientific (BSX) has an average rating of Buy and mean price target of $83.70, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $57.39, Change: $+1.47, Percent Change: +2.63%

$BSX
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding 0.4%.The iShares Biotechnology ETF (IBB) was shedding 1.6%.In corporate news, Boston Scientific (BSX) shares jumped 6% after it said Monday that it invested $1.5 billion for an approximately 34% stake in privately held MiRus, gaining an exclusive option to acquire the company's TAVR business. Separately, Boston Scientific entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase (JPM) as part of its $5 billion share buyback authorization.Claritev (CTEV) shares jumped past 19% after the company issued a response to a Thursday media article stating that the Department of Justice has launched a criminal probe into Claritev. The company said Monday it has not been informed by the DOJ that it is the target of an investigation at no point in the subsequent two years after receiving a 2024 subpoena.Eli Lilly (LLY) was among the pharmaceutical firms highlighted in Monday's Supreme Court order list, which included widespread denials of certiorari in drugmaker-related and other commercial cases, according to the Court's May 18 orders. Lilly shares fell 1.7%.Berkshire Hathaway (BRK.A, BRK.B) said Friday in a regulatory filing that it sold all of its stake in UnitedHealth (UNH). UnitedHealth shares were down 0.8%.

$BSX$CTEV$LLY$UNH
Sectors

Sector Update: Healthcare

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Healthcare Select Sector SPDR ETF (XLV) up 0.3%.The iShares Biotechnology ETF (IBB) was shedding 1.7%.In corporate news, Boston Scientific (BSX) shares jumped past 6% after it said Monday that it invested $1.5 billion for an approximately 34% stake in privately held MiRus, gaining an exclusive option to acquire the company's TAVR business. Separately, Boston Scientific entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase (JPM) as part of its $5 billion share buyback authorization.

$BSX
Wire

Boston Scientific Makes Third Attempt at TAVR Market, Needham Says

Boston Scientific (BSX) is making its third attempt at the Transcatheter Aortic Valve Replacement market with its $1.5 billion investment in MiRus, Needham said in a note Monday.Earlier, Boston said it secured a 34% stake in MiRus that focuses on cardiovascular and orthopedic diseases treatment, including the SIEGEL Balloon Expandable TVAR system."We believe that BSX's third attempt with TAVR could provesuccessful and enable it to capture meaningful market share if the STAR trial meets its endpoints and SIEGEL's differentiated design and features resonate with physicians," the note said.LOTUS TAVR and ACURATE TAVR were removed from the market after each had various issues, the report added."Importantly, the deal's structure limits BSX's risk to its initial $1.5B investment," the report said.Needham reiterated its buy rating with a $77 price target.Price: $55.57, Change: $+2.89, Percent Change: +5.49%

$BSX
Sectors

Sector Update: Healthcare Stocks Decline Pre-Bell Monday

Healthcare stocks were declining pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5% and the iShares Biotechnology ETF (IBB) 0.6% lower.Regeneron Pharmaceuticals (REGN) stock was down more than 11% after the company said two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.Bio-Rad Laboratories (BIO) has attracted a sizable investment from Elliott Investment Management, which plans to push the life-science tools supplier to improve its lagging stock performance, The Wall Street Journal reported, citing people familiar with the matter. Bio-Rad Laboratories shares were up more than 7% premarket.Boston Scientific (BSX) entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase (JPM) as part of its previously announced $5 billion share buyback authorization, the company said. Boston Scientific also said it invested $1.5 billion for an approximately 34% stake in privately held MiRus. Shares of Boston Scientific were up about 2% pre-bell.

$BIO$BSX$IBB$JPM$REGN$XLV
Research

Research Alert: CFRA Lowers Rating On Shares Of Boston Scientific Corporation To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $56 from $100 on 14.4x our 2027 EPS estimate, a discount to BSX's five-year historical forward P/E average. We reduce our 2026 EPS view to $3.32 from $3.40 as we lower our quarterly estimates on margin concerns. We also lower our 2027 EPS forecast to $3.90 from $4.04. While we see healthy growth in procedures and diagnostics in the long run, we are uncertain about the near-term evolution of elective surgeries due to softening demand and weakening consumer sentiment in the U.S., which hit an all-time low in May amid a complex macroeconomic environment. At the same time, we continue to see tariffs as a considerable pressure point on the cost side, as many companies in the industry have global supply chains, while competition is intensifying between BSX, Medtronic, J&J, and Abbott, in our view. Amid these challenges coupled with margin pressures stemming from rising raw material costs and supply chain challenges, we prefer to remain on the sidelines and lower our view to Hold from Buy.

$BSX
Wire

Penumbra is a 'Strong' Strategic fit for Boston Scientific, RBC Says

Penumbra (PEN) is a "strong" strategic and financial fit for Boston Scientific (BSX), which expects the deal to be accretive to its profitable growth profile, RBC Capital Markets said in Wednesday research report.Penumbra delivered an upside revenue surprise in Q1 driven by outperformance in embolization and access segments, while thrombectomy sales lagged, analysts wrote.Q1 sales were primarily attributable to higher sales volume in the US due to further market penetration of products while price remained stable, according to the note.The brokerage said it reiterated its sector perform rating on the stock and price target of $374 per share, pending the deal close in H2.Price: $324.81, Change: $+0.62, Percent Change: +0.19%

$BSX$PEN
Sectors

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 1.5%.In corporate news, Boston Scientific (BSX) shares fell 3.3% after Daiwa Securities downgraded the stock to neutral from outperform, and lowered its price target to $60 per share from $83 earlier.AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected Q1 results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs. Its shares rose 3.7%.AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported. AstraZeneca shares were down 1.1%.KalVista Pharmaceuticals (KALV) and Chiesi Group said Wednesday they have signed an agreement through which Chiesi will buy KalVista for $27 per share in cash, or about $1.9 billion. KalVista shares surged 38%.

$ABBV$AZN$BSX$KALV

Showing 21-40 of 65

Track with the FINWIRES app suite